Bioheart, Inc. (BHRT) - OTCPK - Current
  • Jan. 16, 2015, 12:38 PM
    • Bioheart's (OTCQB:BHRT +1.1%) Board of Directors authorize a share repurchase program, although the size of the buyback is not disclosed.
    | Jan. 16, 2015, 12:38 PM | 2 Comments
  • Aug. 7, 2014, 1:33 PM
    • Bioheart (OTCQB:BHRT +6.9%) Q2 results: Revenues: $819.6K (+999%); Net Income (6 mo.): $226.0K (+117.8%); Cash Burn (6 mo.): ($507.0K) (+53.7%).
    • No guidance given.
    | Aug. 7, 2014, 1:33 PM | 2 Comments
  • Jul. 11, 2014, 6:32 PM
    • As part its restructuring to improve its chances of securing additional financing, Bioheart (BHRT -6.7%) settles a debt of $1,508,219.19 by issuing 37,705,478 shares of common stock. The transaction represents a 7.6% dilution for current shareholders.
    • The current holders of the company's Series A Convertible Preferred Stock have agreed to exchange their shares for shares of common stock contingent upon the company securing financing.
    | Jul. 11, 2014, 6:32 PM
  • Dec. 23, 2008, 3:55 PM

    Among recent IPOs - themselves a rare breed - stocks trading higher than their offer price are even rarer. Grand Canyon Education (LOPE) heads up DJ's IPO scorecard, +44%. Bioheart (BHRT), -81%, has the dubious honor of finishing last.

    | Dec. 23, 2008, 3:55 PM
Company Description
Founded in 1999, Bioheart, Inc. is committed to the development of effective cell technologies to treat cardiovascular diseases. Unlike other organs, the human heart does not have the ability to repair itself once it is damaged. Bioheart's discoveries include multiple cell therapies in various... More
Sector: Healthcare
Industry: Biotechnology
Country: United States